Ftse Mib
34.888,79
0,09%
DAX
20.405,92
-0,11%
S&P 500
6.051,09
0,00%
NASDAQ
19.926,72
0,12%
Bitcoin
101.754,99
0,29%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aclarion Inc (ACONW) Aclarion Inc (ACONW) Notizie

Aclarion Inc

ACONW
0,039
0,00 (0,00%)
13 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Warrant Azionario
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/12/202412:01EDGAR2Form DEF 14A - Other definitive proxy statements
27/11/202422:03EDGAR2Form 8-K - Current report
22/11/202422:03EDGAR2Form PRE 14A - Other preliminary proxy statements
21/11/202414:00GLOBEAclarion Announces Nociscan Featured in RSNA Edition of..
14/11/202419:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202421:06EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
08/11/202422:18EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/11/202412:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/11/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
04/11/202412:15EDGAR2Form S-3 - Registration statement under Securities Act of..
25/10/202423:05EDGAR2Form S-1 - General form for registration of securities under..
11/10/202422:36EDGAR2Form POS AM - Post-Effective amendments for registration..
11/10/202422:20EDGAR2Form 8-K - Current report
10/10/202413:00GLOBEAclarion to Participate in the 2024 Maxim Healthcare Virtual..
01/10/202422:07EDGAR2Form 8-K - Current report
27/9/202412:57GLOBEAclarion's Nociscan AI Plays Key Role in Advanced..
24/9/202422:58EDGAR2Form 8-K - Current report
24/9/202422:54EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23/9/202422:01EDGAR2Form 8-K - Current report
19/9/202423:02EDGAR2Form S-3/A - Registration statement under Securities Act of..
12/9/202412:57GLOBEAclarion Provides Corporate Update on Nociscan AI Technology..
10/9/202412:57GLOBEAclarion Announces Completion of First Nociscan Exams in..
05/9/202412:57GLOBEAclarion Launches Surgeon Partnership to Apply Nociscan’s AI..
29/8/202412:57GLOBEAclarion Launches Second Clinical Utility and Economic..
21/8/202413:57GLOBEAclarion Launches the Clinical Utility and Economic (CLUE)..
15/8/202415:48GLOBEAclarion to Present at August 20th Virtual Investor Summit..
14/8/202414:08GLOBEAclarion Announces First Commercial Agreement in Michigan
13/8/202415:07GLOBEAclarion Hits Another Key Milestone by Adding Vitality -..
09/7/202413:00GLOBEAclarion Achieves Milestone With Key Second Payer Coverage..
26/6/202414:30GLOBEAclarion Announces Initial Payer Coverage of Nociscan by AXA..
25/6/202414:30GLOBEAclarion Expands Commercial Engagement With The London..
18/6/202422:01EDGAR2Form 8-K - Current report
15/5/202421:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
25/4/202415:14GLOBEAclarion’s Nociscan Solution to Play Key Role in..
04/3/202414:00GLOBEAclarion Announces Publication of Compelling Peer-Reviewed..
27/2/202421:22GLOBEAclarion Announces Closing of $3.0 Million Public Offering
26/2/202415:15GLOBEAclarion Announces Pricing of $3.0 Million Public Offering
05/2/202414:00GLOBEAclarion Announces Successful Financings; Plans to Launch..
22/1/202414:00GLOBEAclarion Expands Nociscan Access Into Phoenix With Key..
17/1/202414:00GLOBEAclarion Announces Updated Product Release That Expands MRI..
08/1/202414:00GLOBEAclarion and ATEC Execute Strategic Partnership Agreement to..
02/1/202418:00GLOBEAclarion Announces Reverse Stock Split
Apertura: Min: Max:
Chiusura: 0,039

La tua Cronologia

NASDAQ
ACONW
Aclarion
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network